Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Stock Traders Daily
$20.00
Provider: Pechala's Reports
$15.00
Provider: Pechala's Reports
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Antares Pharma Inc announces publication of a head-to-head, randomized, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis


Thursday, 17 Apr 2014 07:00am EDT 

Antares Pharma Inc:Says the Annals of the rheumatic diseases has published results from an open-label, head-to-head randomized, crossover study comparing the relative bioavailability, safety and tolerability of OTREXUP to oral methotrexate in adult patients with rheumatoid arthritis.Following administration of OTREXUP, the systemic availability increased proportionally at every dose, which extended the range of exposure compared to patients receiving oral therapy.No unexpected adverse events were noted for either formulation in this short term study and higher systemic MTX exposure was not associated with increases in adverse events. 

Company Quote

57.1
-0.72 -1.25%
22 Aug 2014